To evaluate and to compare efficacy and safety of a dual regimen with oral modified release tacrolimus FK506E (MR4) / steroids versus a dual regimen with oral tacrolimus FK506 / steroids in patients undergoing primary liver transplantation. It shall be demonstrated that FK506E (MR4) is non-inferior to FK506 with regards to the primary endpoint.
A multicentre, 1:1 randomised, double blind, double dummy, two arm parallel group phase III study comparing a dual modified release FK506E (MR4) / steroid regimen with a standard tacrolimus FK506 / steroid regimen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
475
immunosuppression
Incidence of and time to biopsy-proven acute rejections
Time frame: 12 months
Incidence of acute rejections
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Heidelberg, Australia
Unnamed facility
Sydney, Australia
Unnamed facility
Ghent, Belgium
Unnamed facility
Liège, Belgium
Unnamed facility
Bel Horizonte, Brazil
Unnamed facility
Porto Alegre, Brazil
Unnamed facility
Rio de Janeiro, Brazil
Unnamed facility
São Paulo, Brazil
Unnamed facility
Edmonton, Alberta, Canada
Unnamed facility
Vancouver, British Columbia, Canada
...and 41 more locations